M-M-R II

Simultaneous vaccination against MMR in individuals ≥12 mth.

IM/SC Approx 0.5 mL into the outer aspect of upper arm. Recommended vaccination schedule Individual 1st vaccinated at ≥12 mth Should be revaccinated at 4-6 yr. Measles outbreak schedule Infant 6-12 mth May recommend vaccination in outbreak situations. Administer 2nd dose at 12-15 mth followed by revaccination at 4-6 yr. Use w/ other vaccines Administer 1 mth before or after administration of other live viral vaccines. SC Patient w/ thrombocytopenia or any coagulation disorder Approx 0.5 mL into the outer aspect of upper arm.

Hypersensitivity to any vaccine component including gelatin; anaphylactic/anaphylactoid reactions to neomycin (contains approx neomycin 25 mcg). Any febrile resp illness or other active febrile infection. Active untreated TB. Patients receiving immunosuppressive therapy except those receiving corticosteroids as replacement therapy (eg, for Addison's disease). Individuals w/ blood dyscrasias, leukemia, lymphomas of any type or other malignant neoplasms affecting bone marrow or lymphatic systems. Primary & acquired immunodeficiency states including immunosuppressed patients associated w/ AIDS or other clinical manifestations of HIV infection, cellular immune deficiencies, hypogammaglobulinemic & dysgammaglobulinemic states. Individuals w/ family history of congenital or hereditary immunodeficiency. Pregnancy; avoid pregnancy for 1 mth in postpubertal females who have undertaken vaccination.

Adequate treatment provisions including epinephrine inj should be available for immediate use should anaphylactic or anaphylactoid reaction occur. May enhance risk of immediate-type hypersensitivity reactions after receiving vaccines containing chick embryo antigen traces in persons w/ history of anaphylactic, anaphylactoid or other immediate reactions (eg, hives, mouth & throat swelling, difficulty breathing, hypotension or shock) subsequent to egg ingestion. Do not inj intravascularly. Individual or family history of convulsions, cerebral injury or any other condition in which stress due to fever should be avoided. Bleeding may occur following IM administration in individuals w/ thrombocytopenia or any coagulation disorder; give SC in individuals w/ thrombocytopenia or any coagulation disorder. Individuals w/ current thrombocytopenia may develop more severe thrombocytopenia following vaccination. Individuals who experienced thrombocytopenia w/ 1st dose of M-M-R II (or its component vaccines) may develop thrombocytopenia w/ repeat doses. Closely monitor HIV-infected vaccinees for vaccine-preventable diseases. Possible measles inclusion body encephalitis, pneumonitis & fatal outcome in severely immunocompromised individuals inadvertently vaccinated w/ measles-containing vaccine. May result in temporary tuberculin skin sensitivity depression. Administer tuberculin test either before, simultaneously w/ or at least 4-6 wk after M-M-R II. May not protect 100% of vaccinees. Do not give Ig concurrently. Individuals planning to travel abroad (if not immune) can acquire MMR. Vaccination has been recommended for susceptible individuals in high-risk groups (eg, college students, healthcare workers & military personnel). Vaccination of individuals exposed to wild-type measles may provide some protection if vaccinated w/in 72 hr of exposure. Not recommended for concurrent use w/ routine DPT administration &/or oral poliovirus vaccine. Immunization of susceptible non-pregnant adolescent & adult females of childbearing age. Advise women of childbearing age not to become pregnant for 1 mth after vaccination. Inform postpubertal females of frequent occurrence of generally self-limited arthralgia &/or arthritis beginning 2-4 wk after vaccination. Previously unvaccinated childn >12 mth who are in contact w/ susceptible pregnant woman should receive live attenuated rubella vaccine to reduce risk of exposure of the pregnant woman. Lactation. Childn under TB treatment who have not experienced disease exacerbation when immunized w/ live measles virus vaccine; untreated tuberculous childn. Infant <6 mth (measles) & <12 mth (mumps & rubella).

Short duration burning &/or stinging at inj site. Fever; rash or measles-like rash (usually minimal but may be generalized).

Concurrent administration w/ Ig may interfere w/ expected immune response; defer vaccination for ≥3 mth following administration of Ig (human) & blood/plasma transfusions.

Vaccines, Antisera & Immunologicals

J07BD52 - measles, combinations with mumps and rubella, live attenuated ; Belongs to the class of morbilli viral vaccines.

POM